Cargando…

The Prognostic Value of Excision Repair Cross-Complementation Group 1 (ERCC1) in Patients with Small Cell Lung Cancer (SCLC) Receiving Platinum-Based Chemotherapy: Evidence from Meta-Analysis

Recently, the correlation between the efficacy of platinum-based chemotherapy and ERCC1 expression in patients with SCLC has attracted wide-spread attention, and a lot of investigations have been conducted, whereas conflicting results were presented. Therefore, we performed the present meta-analysis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yanlong, Luo, Xiuping, Yang, Nuo, Feng, Ronghao, Xian, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222940/ https://www.ncbi.nlm.nih.gov/pubmed/25375151 http://dx.doi.org/10.1371/journal.pone.0111651

Ejemplares similares

The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy
por: Tendler, Salomon, et al.
Publicado: (2020)

ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy
por: Xian-jun, Feng, et al.
Publicado: (2014)

Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy
por: Li, Mu-Xing, et al.
Publicado: (2016)

Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis
por: Lv, Yalei, et al.
Publicado: (2021)

Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations
por: Hubner, Richard A., et al.
Publicado: (2011)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer
por: Dudás, József, et al.
Publicado: (2014)

Excision repair cross-complementing group 1 (ERCC1) overexpression inhibits cell apoptosis and is associated with unfavorable prognosis of esophageal squamous cell carcinoma
por: Peng, Haiying, et al.
Publicado: (2018)

Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin
por: Rao, Devika, et al.
Publicado: (2019)

Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy
por: Pongmaneratanakul, Skolchart, et al.
Publicado: (2017)

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer
por: Matsubara, J, et al.
Publicado: (2008)

Excision repair cross-complementing group 1 (ERCC1) overexpression inhibits cell apoptosis and is associated with unfavorable prognosis of esophageal squamous cell carcinoma: Erratum
Publicado: (2018)

Nucleotide Excision Repair Gene ERCC2 and ERCC5 Variants Increase Risk of Uterine Cervical Cancer
por: Joo, Jungnam, et al.
Publicado: (2016)

Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer
por: Mountzios, Giannis, et al.
Publicado: (2008)

Disruption of DNA repair in cancer cells by ubiquitination of a destabilising dimerization domain of nucleotide excision repair protein ERCC1
por: Yang, Lanlan, et al.
Publicado: (2017)

ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy
por: Palomba, Grazia, et al.
Publicado: (2014)

ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy
por: Baiomy, Mohamed Ali EL, et al.
Publicado: (2017)

The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy
por: Wahba, Nagwa Ismail, et al.
Publicado: (2023)

A miR‐15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum‐based chemotherapy
por: Xue, Ping, et al.
Publicado: (2022)

ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Baek, Moo-Jun
Publicado: (2015)

XPF-ERCC1 protects liver, kidney and blood homeostasis outside the canonical excision repair pathways
por: Mulderrig, Lee, et al.
Publicado: (2020)

Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy
por: Yamashita, Fumie, et al.
Publicado: (2013)

The ZEB2‐dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer
por: Sreekumar, Rahul, et al.
Publicado: (2021)

Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
por: Tang, Ning, et al.
Publicado: (2017)

Study of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers
por: Abyarghamsari, Mahdiye, et al.
Publicado: (2019)

X-Ray Repair Cross Complementing Protein 1 in Base Excision Repair
por: Hanssen-Bauer, Audun, et al.
Publicado: (2012)

Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy
por: Kim, Miso, et al.
Publicado: (2015)

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada
por: Elegbede, Anifat A., et al.
Publicado: (2021)

Precise prediction of the sensitivity of platinum chemotherapy in SCLC: Establishing and verifying the feasibility of a CT-based radiomics nomogram
por: Su, Yanping, et al.
Publicado: (2023)

ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy
por: Liblab, Salisa, et al.
Publicado: (2020)

Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study
por: Piljić Burazer, Marina, et al.
Publicado: (2019)

Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population
por: Wu, Xiaoqing, et al.
Publicado: (2023)

Germline ERCC excision repair 6 like 2 ( ERCC6L2 ) mutations lead to impaired erythropoiesis and reshaping of the bone marrow microenvironment
por: Armes, Hannah, et al.
Publicado: (2022)

XPF–ERCC1: Linchpin of DNA crosslink repair
por: McHugh, Peter J.
Publicado: (2020)

The prognostic value of excision repair cross-complementing Group 1 expression in nasopharyngeal cancer patients
por: Chitapanarux, Imjai, et al.
Publicado: (2020)

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
por: Li, P, et al.
Publicado: (2013)

ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy
por: Ryu, Hyewon, et al.
Publicado: (2017)

Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study
por: Morimoto, Kenji, et al.
Publicado: (2022)

High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer
por: Du, Pei, et al.
Publicado: (2016)

Deletion of the Nucleotide Excision Repair Gene Ercc1 Reduces Immunoglobulin Class Switching and Alters Mutations Near Switch Recombination Junctions
por: Schrader, Carol E., et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_j285km3608a1hk0eudqa3prcot